胰腺癌合并糖尿病围手术期管理研究进展

doi:10.3969/j.issn.1002-3070.2010.05.025

PRACTICAL ONCOLOGY JOURNAL ›› 2010, Vol. 24 ›› Issue (5): 490-493.doi: 10.3969/j.issn.1002-3070.2010.05.025

Previous Articles Next Articles

Received:2010-07-02 Online:2010-10-28 Published:2015-01-24

Abstract

CLC Number:

R735.9

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.3969/j.issn.1002-3070.2010.05.025

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2010/V24/I5/490

[1]	XU Ting, CHENG Hua, ZHANG Wei. Research progress in the early diagnosis and minimally invasive surgical treatment of elderly pancreatic cancer [J]. Journal of Practical Oncology, 2023, 37(3): 257-261.
[2]	GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 502-506.
[3]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[4]	HU Zongtao, LIU Yan, GAO Shile, GAN Chen, ZHANG Yongkang. The clinical efficacy and safety evaluation of high-dose and fractionated radiotherapy combined with albumin-bound paclitaxel and Tiggio chemotherapy in patients with locally advanced pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(2): 144-149.
[5]	LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 49-53.
[6]	ZHANG Wenjing, LIU Jinshuang, WANG Dan, LI Qingwei, LI Zhiwei. Research status of neoadjuvant therapy for pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 64-68.
[7]	LUO Gan, YI Chao, YIMAMUMAIMAITIJIANGo Abula, XU Lin, YIN Jiwei, DING Wei. Expression of Notch signaling pathway in pancreatic cancer and its role [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 1-7.
[8]	PEI Lei, CAI Ceng, MAO Rui, Ailijang.Tu-er-xun, ZHAO Huarong, ZHANG Hua, BAO Yongxing. Prognostic analysis of 313 aged pancreatic cancer patients in hospital treatment between Uygur and Han nationality in Xinjiang area [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 1-6.
[9]	LIU Xian, REN Gang, LI Liqin, ZHU Fuhai, XIA Tingyi. Analysis of relative factors on gastrointestinal toxicity with TOMO hypofractioned radiotherapy for pancreatic adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(6): 481-486.
[10]	ZHAN Chao,JIN Yu,ZHANG Yubao. Comparison between CA19-9,CEA and specific N-Glycans in early middle stage pancreatic carcinoma serum [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 7-11.
[11]	XU Jingjing,YANG Ming,ZHAO Juan,ZHOU Yanhua,ZHANG Yanqiao. Clinical analysis of prognostic factors in the postoperative pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(6): 543-547.
[12]	. [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(5): 453-456.
[13]	GU Haitao, SHI Xin, LIN Shibo, ZHANG Yi, YANG Jun, QIAN Chengjia. The expression and significance of PTEN and PIK3CA in pemetrexed-resistant human pancreatic cancer cell line Patu8988 [J]. PRACTICAL ONCOLOGY JOURNAL, 2010, 24(2): 112-116.
[14]	LUAN Jinwei, YOU Qingshan. Effects of 3D-CRT combined with chemotherapy and chemotherapy alone in advanced pancneatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(4): 328-331.
[15]	. [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(4): 350-352.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments